Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Human Mutation

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/humu.21327PMID 20672374PMCID PMC2970726
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes.

  2010cited by this paper
• When diseases disappear--the case of familial dysautonomia.

  2009cited by this paper
• Next-generation sequencing: from basic research to diagnostics.

  2009cited by this paper
• Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent.

  2009cited by this paper
• ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent.

  2009cited by this paper
• Carrier frequency of autosomal‐recessive disorders in the Ashkenazi Jewish population: should the rationale for mutation choice for screening be reevaluated?

  2008influential reference
• Carrier screening in individuals of Ashkenazi Jewish descent

  2008influential reference
• Array-Based Resequencing Assay for Mutations Causing Hypertrophic Cardiomyopathy

  2008cited by this paper
• Population screening in a Druze community: the challenge and the reward

  2008cited by this paper
• Keeping up with the next generation: massively parallel sequencing in clinical diagnostics.

  2008cited by this paper
• Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population

  2008influential reference
• Knowledge and Attitude Toward the Hemoglobinopathies Premarital Screening Program in Saudi Arabia: Population-Based Survey

  2008cited by this paper
• Mutations causing severe combined immunodeficiency: detection with a custom resequencing microarray

  2008cited by this paper
• Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.

  2007cited by this paper
• Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population.

  2007cited by this paper
• Biochemical and molecular diagnosis of lipoamide dehydrogenase deficiency in a North American Ashkenazi Jewish family

  2006cited by this paper
• Technical validation of a TM Biosciences Luminex-based multiplex assay for detecting the American College of Medical Genetics recommended cystic fibrosis mutation panel.

  2006cited by this paper
• The frequency of mucolipidosis type IV in the Ashkenazi Jewish population and the identification of 3 novel MCOLN1 mutations

  2005cited by this paper
• Technical validation of a multiplex platform to detect thirty mutations in eight genetic diseases prevalent in individuals of Ashkenazi Jewish descent

  2005influential reference
• Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers

  2005cited by this paper
• Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies

  2005cited by this paper
• Detection of large-scale variation in the human genome

  2004cited by this paper
• Canavan disease: Carrier‐frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay

  2004cited by this paper
• Nemaline myopathy in the Ashkenazi Jewish population is caused by a deletion in the nebulin gene

  2004influential reference
• Premarital and prenatal screening for cystic fibrosis: Experience in the Ashkenazi Jewish population

  2004cited by this paper
• Molecular screening for diseases frequent in Ashkenazi Jews: Lessons learned from more than 100,000 tests performed in a commercial laboratory

  2004influential reference
• Cystic fibrosis carrier screening: Validation of a novel method using BeadChip technology

  2004cited by this paper
• Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel

  2004cited by this paper
• Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population

  2004cited by this paper
• The R245X Mutation of PCDH15 in Ashkenazi Jewish Children Diagnosed with Nonsyndromic Hearing Loss Foreshadows Retinitis Pigmentosa

  2004influential reference
• ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent.

  2004cited by this paper
• Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III

  2003cited by this paper
• Screening for Familial Dysautonomia in Israel: Evidence for Higher Carrier Rate among Polish Ashkenazi Jews

  2003cited by this paper
• A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome.

  2003cited by this paper
• Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: Possible beneficial effect of vitamin therapy

  2003influential reference
• Familial dysautonomia: detection of the IKBKAP IVS20(+6T --> C) and R696P mutations and frequencies among Ashkenazi Jews.

  2002cited by this paper
• Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population.

  2002cited by this paper
• Bloom syndrome and Fanconi's anemia: rate and ethnic origin of mutation carriers in Israel.

  2002influential reference
• Screening for thalassemia: a model of success.

  2002cited by this paper
• Usher syndrome: from genetics to pathogenesis.

  2001influential reference
• Laboratory standards and guidelines for population-based cystic fibrosis carrier screening

  2001cited by this paper
• Experiences in molecular-based prenatal screening for Ashkenazi Jewish genetic diseases.

  2001cited by this paper
• Cystic fibrosis population carrier screening: Here at last—Are we ready?

  2001cited by this paper
• Mucolipidosis type IV: Novel MCOLN1 mutations in Jewish and non‐Jewish patients and the frequency of the disease in the Ashkenazi Jewish population

  2001cited by this paper
• The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease.

  2001cited by this paper
• Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the Ashkenazi Jewish population.

  2001cited by this paper
• Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model

  2000cited by this paper
• Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews.

  1999influential reference
• High Frequency of a Common Bloom Syndrome Ashkenazi Mutation Among Jews of Polish Origin

  1998influential reference
• Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population.

  1998cited by this paper
• Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population

  1998influential reference
• Prenatal genetic carrier testing using triple disease screening.

  1997cited by this paper
• Niemann–Pick Disease: Mutation Update, Genotype/Phenotype Correlations, and Prospects for Genetic Testing

  1997influential reference
• Cystic Fibrosis Heterozygote Screening in the Orthodox Community of Ashkenazi Jews: The Dor Yesharim Approach and Heterozygote Frequency

  1996cited by this paper
• Mutations in the sulonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews.

  1996influential reference
• Population‐specific screening by mutation analysis for diseases frequent in Ashkenazi Jews

  1996cited by this paper
• Carrier frequency of the IVS4 + 4 A-->T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population.

  1995cited by this paper
• The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel.

  1994cited by this paper
• Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network.

  1993cited by this paper
• Screening for carriers of Tay-Sachs disease in the ultraorthodox Ashkenazi Jewish community in Israel.

  1993cited by this paper

• Social and Demographic Determinants of Consanguineous Marriage: Insights from a Literature Review

  2025cites this paper
• Recognizing Gaucher disease in the fifth decade and beyond: a retrospective case study in patients of Ashkenazi Jewish descent

  2025cites this paper
• Cerebrotendinous Xanthomatosis occurs at high frequency in Ashkenazi Jews.

  2025cites this paper
• Correlation of Plasma Lyso-GL1 Levels with Clinical Phenotype and Treatment Decisions in Patients with Gaucher Disease.

  2025cites this paper
• Long-Read Sequencing Unveils an Intronic ASPA Retrotransposon Variant Implicated in Canavan Disease.

  2025cites this paper
• Genetic disease risks of under-represented founder populations in New York City

  2025cites this paper
• Ellipsoid Zone Loss as an Outcome Measure in MAK-Associated Retinitis Pigmentosa.

  2025cites this paper
• The natural history of dihydrolipoamide dehydrogenase deficiency in Israel

  2024cites this paper
• GM2 Gangliosidosis: Whole-Exome Sequencing Reveals Novel Homozygous Pathogenic Variant within the HEXA Gene in Iranian Family

  2024cites this paper
• Applications of genome sequencing as a single platform for clinical constitutional genetic testing

  2024cites this paper
• Allele frequency of pathogenic variants causing acid sphingomyelinase deficiency and Gaucher disease in the general Japanese population

  2024cites this paper
• Genetic disease risks of under-represented founder populations in New York City

  2024cites this paper
• Glycogen storage diseases: An update

  2023cites this paper
• Biochemical characterization of patients with dihydrolipoamide dehydrogenase deficiency

  2023cites this paper
• Genetic Testing in Clinical Movement Disorders: A Case-Based Review

  2023cites this paper
• Expanded Carrier Screening

  2022cites this paper
• Pathogenic variants carrier screening in New Brunswick: Acadians reveal high carrier frequency for multiple genetic disorders

  2022cites this paper
• Long‐read HiFi sequencing of NUDT15: Phased full‐gene haplotyping and pharmacogenomic allele discovery

  2022cites this paper
• Expanded carrier screening in the United States: A systematic evidence review exploring client and provider experiences

  2022cites this paper
• In Silico Analysis of the Molecular-Level Impact of SMPD1 Variants on Niemann-Pick Disease Severity

  2021cites this paper
• Evaluating the model of offering expanded genetic carrier screening to high school students within the Sydney Jewish community

  2021cites this paper
• The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment

  2021cites this paper
• Systematic review of outcomes in studies of reproductive genetic carrier screening: Towards development of a core outcome set.

  2021cites this paper
• A collaborative genetic carrier screening model for the British Ashkenazi Jewish community

  2021cites this paper
• Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs

  2021cites this paper
• The phenotypic spectrum of dihydrolipoamide dehydrogenase deficiency in Saudi Arabia

  2021cites this paper
• Carrier screening in the Mexican Jewish community using a pan-ethnic expanded carrier screening NGS panel.

  2021cites this paper
• A review of milk gangliosides: Occurrence, biosynthesis, identification, and nutritional and functional significance

  2021cites this paper
• A collaborative genetic carrier screening model for the British Ashkenazi Jewish community

  2021cites this paper
• Practicing Prenatal Medicine in a Genomic Future: How the Practice of Pediatrics May (Or May Not) Change with the Introduction of Widespread Prenatal Sequencing

  2021cites this paper
• Delivery of Preconception Counselling Services: The Snags of Health Care Service Providers.

  2021cites this paper
• Beyond the “Jewish panel”: the importance of offering expanded carrier screening to the Ashkenazi Jewish population

  2020cites this paper
• Practices in synagogues regarding Jewish genetic disease education

  2020cites this paper
• The N370S/R496H genotype in type 1 Gaucher disease – Natural history and implications for pre symptomatic diagnosis and counseling

  2020cites this paper
• Expanded Carrier Screening

  2020cites this paper
• Attitudes towards genetic information delivered by high-throughput sequencing among clinical molecular Geneticists, genetic counselors, medical advisors and students in France.

  2020cites this paper
• ‘We are all in the image of God’: reproductive imaginaries and prenatal genetic testing in American Jewish communities

  2020cites this paper
• Genetic Testing

  2020cites this paper
• Discovery of Novel Inhibitors of a Critical Brain Enzyme Using a Homology Model and a Deep Convolutional Neural Network.

  2020cites this paper
• Tay-Sachs disease

  2019cites this paper
• Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.

  2019cites this paper
• Expanded carrier screening for autosomal recessive conditions in health care: Arguments for a couple‐based approach and examination of couples' views

  2019cites this paper
• An Updated View on the Molecular Pathomechanisms of Human Dihydrolipoamide Dehydrogenase Deficiency in Light of Novel Crystallographic Evidence

  2019cites this paper
• Expanded universal carrier screening and its implementation within a publicly funded healthcare service

  2019cites this paper
• How does carrier status for recessive disorders influence reproductive decisions? A systematic review of the literature

  2019cites this paper
• Comparison of pan‐ethnic and ethnic‐based carrier screening panels for individuals of Ashkenazi Jewish descent

  2019cites this paper
• Health Challenges of the Pacific Region: Insights From History, Geography, Social Determinants, Genetics, and the Microbiome

  2019cites this paper
• Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay–Sachs disease

  2019cites this paper
• Patients’ Opinions on Genetic Counseling on the Increased Risk of Parkinson Disease among Gaucher Disease Carriers

  2018cites this paper
• Ethnicity-Based Carrier Screening.

  2018cites this paper
• Implementation of a Carrier Screening Program in a High-Risk Undergraduate Student Population Using Digital Marketing, Online Education, and Telehealth

  2018cites this paper
• Prenatal Diagnosis of Tay-Sachs Disease.

  2018cites this paper
• Machine learning approaches and web-based system to the application of disease modifying therapy for sickle cell

  2018cites this paper
• Founder Ashkenazi Jewish mutations of large deletion in the inherited retinal dystrophy genes

  2018cites this paper
• Choroba Gauchera – zalecenia dotyczące rozpoznawania, leczenia i monitorowania

  2017cites this paper
• Analysis of the relationship between functional divergence and the propensity of duplicated genes to be involved in human Mendelian diseases

  2017cites this paper
• Human dihydrolipoamide dehydrogenase (E3) deficiency: Novel insights into the structural basis and molecular pathomechanism.

  2017cites this paper
• Lysosomal storage disorders: Sphingolipidoses

  2017cites this paper
• Machine learning approaches to the application of disease modifying therapy for sickle cell using classification models

  2017cites this paper
• Mutation Frequency of Three Neurodegenerative Lysosomal Storage Diseases: From Screening to Treatment?

  2017cites this paper
• A closer look at expanded carrier screening from a PGD perspective

  2017cites this paper
• Comprehensive population screening in the Ashkenazi Jewish population for recurrent disease‐causing variants

  2017cites this paper
• Targeted sequencing identifies a novel SH2D1A pathogenic variant in a Chinese family: Carrier screening and prenatal genetic testing

  2017cites this paper
• A REVIEW ON PRECISION MEDICINE AND ITS ADVANTAGES

  2017cites this paper
• Expanded carrier screening: A review of early implementation and literature.

  2016cites this paper
• Genetic Carrier Screening in the Twenty-first Century.

  2016cites this paper
• Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening

  2016cites this paper
• Clinical genomics can facilitate countrywide estimation of autosomal recessive disease burden

  2016cites this paper
• Carrier screening in the era of expanding genetic technology

  2016cites this paper
• MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia

  2016cites this paper
• Responsible implementation of expanded carrier screening

  2016cites this paper
• Expanding preconception carrier screening for the Jewish population using high throughput microfluidics technology and next generation sequencing

  2016cites this paper
• Carrier screening by next‐generation sequencing: health benefits and cost effectiveness

  2016cites this paper
• Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment.

  2016cites this paper
• A novel frameshift mutation of HEXA gene in the first family with classical infantile Tay-Sachs disease in Thailand

  2016cites this paper
• 1 Ethiek van de voortplantingsgeneeskunde

  2016cites this paper
• Tay Sachs Disease: Analysis Of Australian Screening Strategies (1995-2013)

  2016cites this paper
• Molecular Genetics and Metabolism

  2015cites this paper
• A founder mutation in the TCIRG1 gene causes osteopetrosis in the Ashkenazi Jewish population

  2015cites this paper
• Changing trends in carrier screening for genetic disease in the United States

  2015cites this paper
• Molecular Genetics and Prenatal Diagnosis

  2015cites this paper
• The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies.

  2015cites this paper
• A rigorous approach for selection of optimal variant sets for carrier screening with demonstration of clinical utility

  2015influential citation
• The clinical management of Type 2 Gaucher disease.

  2015cites this paper
• Evaluation of two-year Jewish genetic disease screening program in Atlanta: insight into community genetic screening approaches

  2015cites this paper
• Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening.

  2015cites this paper
• Do people from the Jewish community prefer ancestry-based or pan-ethnic expanded carrier screening?

  2015cites this paper
• SMPD1 mutations and Parkinson disease.

  2015cites this paper
• Carrier testing for Ashkenazi Jewish disorders in the prenatal setting: navigating the genetic maze.

  2014cites this paper
• Race/ethnicity in biomedical research and clinical practice.

  2014cites this paper
• Ashkenazi Jewish genetic testing: utilisation of services, genetic knowledge and perceptions of stigma

  2014cites this paper
• Implementing Clinical Pharmacogenetics: Point-of-Care and Pre-Emptive Testing

  2014cites this paper
• Adult genetic risk screening.

  2014cites this paper
• mutations origin an update of gaucher mutations distribution in the ashkenazi Jewish Population : Prevalence and country of origin of the mutation r 496 H

  2014cites this paper
• Mutation Update: The Spectra of Nebulin Variants and Associated Myopathies

  2014cites this paper
• Genetic movement disorders in patients of Jewish ancestry.

  2014cites this paper
• A founder mutation in COL4A3 causes autosomal recessive Alport syndrome in the Ashkenazi Jewish population

  2014cites this paper
• Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance.

  2014cites this paper
• Pharmacogenetics in Jewish populations

  2014cites this paper
• Validation for clinical use of, and initial clinical experience with, a novel approach to population-based carrier screening using high-throughput, next-generation DNA sequencing.

  2014cites this paper